Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Current assets
Cash and cash equivalents	$ 1,535	$ 11,780
Prepaid expenses, deposits and other	660	1,478
Clinical trial deposit	1,075
Total current assets	3,270	13,258
Clinical trial deposit		2,600
Property and equipment, net	709	90
Total assets	3,979	15,948
Current liabilities
Accounts payable and accrued liabilities	2,784	3,269
Related party payables	298	721
Total current liabilities	3,082	3,990
Milestone payment liability	166	163
Total liabilities	3,248	4,153
Stockholders’ equity
Common stock Authorized 75,000 shares at June 30, 2023 (June 30, 2022 - 5,500), $0.001 par value Issued and outstanding 1,692 issued at June 30, 2023 (June 30, 2022 1,311)	2	1
Additional paid-in capital	141,438	135,575
Accumulated deficit	(151,375)	(136,356)
Accumulated other comprehensive income	21	21
Total stockholders’ equity	731	11,795
Total liabilities and stockholders’ equity	3,979	15,948
Preferred Stock Series A
Stockholders’ equity
Preferred stock	279	279
Preferred Stock Series C
Stockholders’ equity
Preferred stock	$ 10,366	$ 12,275